Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
63 hedge funds and large institutions have $59.1M invested in Paratek Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 22 reducing their positions, and 18 closing their positions.
406% more call options, than puts
Call options by funds: $172K | Put options by funds: $34K
39% more capital invested
Capital invested by funds: $42.6M → $59.1M (+$16.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 76 → 63 (-13)
18% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 22
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$4.7M |
| 2 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$2.06M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.71M |
| 4 |
EP
Eversept Partners
New York
|
+$1.26M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$468K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.93M |
| 2 |
Millennium Management
New York
|
-$982K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$720K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$401K |
| 5 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$332K |
PRTK Hedge Fund Activity: Q1 2023 in Review
63 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2023, worth a combined $59.1M — up 39% from $42.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PRTK and 7 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 18 added.
The largest buyer was Nexpoint Asset Management, adding an estimated $4.7M. The largest seller was AIGH Capital Management, cutting an estimated $2.93M.
- 63 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2023, down from 76 in Q4 2022.
- Funds reported $59.1M of Paratek Pharmaceuticals, Inc. stock for Q1 2023, up 39% quarter-over-quarter.
- 7 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2023 and 18 closed out, a net change of -11 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2023 was Nexpoint Asset Management, an estimated $4.7M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2023 was AIGH Capital Management, an estimated $2.93M sold.
Based on aggregated 13F filings for Q1 2023.